INMB — Inmune Bio Income Statement
0.000.00%
Last trade - 00:00- $148.08m
- $128.75m
- $0.01m
Annual income statement for Inmune Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.011 | 0.181 | 0.374 | 0.155 | 0.014 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 12.2 | 29.3 | 26.3 | 29.9 | 42.6 |
| Operating Profit | -12.2 | -29.2 | -26 | -29.7 | -42.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.1 | -30.3 | -27.3 | -30 | -42.1 |
| Net Income After Taxes | -12.1 | -30.3 | -27.3 | -30 | -42.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.1 | -30.3 | -27.3 | -30 | -42.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.1 | -30.3 | -27.3 | -30 | -42.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.01 | -1.88 | -1.52 | -1.67 | -2.11 |